A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described (DAROL)
Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients
Sponsor: Bayer
A observational or N/A phase clinical study on Prostate Cancer, this trial is ongoing. The trial is conducted by Bayer and has accumulated 70 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
70 versions recorded-
Apr 16, 2026 — Present [daily]
Active Not Recruiting
-
Feb 2026 — Apr 2026 [monthly]
Active Not Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting
▶ Show 65 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting
-
Apr 2024 — Jun 2024 [monthly]
Active Not Recruiting
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jan 2024 — Feb 2024 [monthly]
Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Recruiting
-
Nov 2023 — Dec 2023 [monthly]
Recruiting
-
Oct 2023 — Nov 2023 [monthly]
Recruiting
-
Sep 2023 — Oct 2023 [monthly]
Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Recruiting
-
Jul 2023 — Aug 2023 [monthly]
Recruiting
-
Jun 2023 — Jul 2023 [monthly]
Recruiting
-
Apr 2023 — Jun 2023 [monthly]
Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Recruiting
-
Feb 2023 — Mar 2023 [monthly]
Recruiting
-
Jan 2023 — Feb 2023 [monthly]
Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Recruiting
-
Nov 2022 — Dec 2022 [monthly]
Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Recruiting
-
May 2022 — Jun 2022 [monthly]
Recruiting
-
Apr 2022 — May 2022 [monthly]
Recruiting
-
Mar 2022 — Apr 2022 [monthly]
Recruiting
-
Feb 2022 — Mar 2022 [monthly]
Recruiting
-
Jan 2022 — Feb 2022 [monthly]
Recruiting
-
Dec 2021 — Jan 2022 [monthly]
Recruiting
-
Nov 2021 — Dec 2021 [monthly]
Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Recruiting
-
Apr 2021 — Jun 2021 [monthly]
Recruiting
-
Mar 2021 — Apr 2021 [monthly]
Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Recruiting
-
Nov 2020 — Dec 2020 [monthly]
Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Recruiting
-
Sep 2020 — Oct 2020 [monthly]
Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Recruiting
-
Jun 2020 — Jul 2020 [monthly]
Recruiting
-
May 2020 — Jun 2020 [monthly]
Recruiting
-
Apr 2020 — May 2020 [monthly]
Recruiting
-
Mar 2020 — Apr 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Feb 2020 — Mar 2020 [monthly]
Not Yet Recruiting
-
Jan 2020 — Feb 2020 [monthly]
Not Yet Recruiting
-
Dec 2019 — Jan 2020 [monthly]
Not Yet Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body. When a patient is enrolled to the study, his/her physician would have already made the decision to treat patient with darolutamide per local standard practice.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .